Brief: Lipella Pharmaceuticals Announces FDA Type C Meeting For LP-10 For Hemorrhagic Cystitis
03/04/2024 13:44
April 3 (Reuters) - Lipella Pharmaceuticals Inc
LIPO.O :
* LIPELLA PHARMACEUTICALS ANNOUNCES FDA TYPE C MEETING FOR
LP-10
FOR HEMORRHAGIC CYSTITIS
* LIPELLA PHARMACEUTICALS - FDA GRANTED TYPE C MEETING
REQUEST TO
DISCUSS CO'S PROPOSED PHASE-2B CLINICAL TRIAL DESIGN FOR
EVALUATION OF LP-10
* LIPELLA PHARMACEUTICALS INC - EXPECTS TO MEET WITH FDA ON
MAY 21
Source text for Eikon: ID:nGNX96MSFY
Further company coverage: LIPO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lipella Pharmaceuticals
See all newsBrief: Lipella Pharmaceuticals Says Bankruptcy Court Approves Sale And Asset Purchase Agreement On June 4
Brief: Lipella Pharmaceuticals Inc. Files Voluntary Petitions For Relief Under Chapter 11
Brief: Lipella Pharmaceuticals Announces Positive Final Results From Phase 2a Study Of LP-10 In Oral Lichen Planus
Brief: Lipella Pharmaceuticals Announces Delisting From Nasdaq Capital Market
U.S. STOCKS ON THE MOVE-Marriott International, Coty, Carlyle Group